AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6609521 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (Abboticin) in standard dosage for the last 10 days before surgery
Number of subjects: 75
Study 6609521 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 75
Study 6609521 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (Abboticin)
Number of subjects: 75
Study 31579048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 414
Study 31579048 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 414
Study 31579048 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms based on clinicopathologic factors
Number of subjects: 414
Study 28506134 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg BIW
Number of subjects: 307
Study 28506134 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (ETN) 50 mg QW
Number of subjects: 307
Study 26883052 — intervention group
Group type: EXPERIMENTAL
Intervention: Plan-It Commander (serious game intervention)
Number of subjects: 170
Study 26883052 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 170
Study 24429167 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 29
Study 24429167 — intervention group
Group type: COMPARATOR
Intervention: Etanercept alone
Number of subjects: 29
Study 24429167 — intervention group
Group type: COMPARATOR
Intervention: Combination of MTX and etanercept
Number of subjects: 29
Study 21988494 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA)
Number of subjects: 10
Study 21988494 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 10
Study 21988494 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 10
Study 20651609 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous variant genotypes for SLC19A1 IVS4(2117) C>T, IVS5(9148) C>A, and wild-type genotype for exon6(2522) C>T
Number of subjects: 54
Study 20651609 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous TC genotype for GGH IVS5(1042) T>C
Number of subjects: 54
Study 20651609 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous (GA) for the FPGS IVS1 (28) G>A polymorphism
Number of subjects: 54
Study 17365851 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (9.9 g dose)
Number of subjects: 14
Study 17365851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16305652 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo administration for 6 months
Number of subjects: 30
Study 11889776 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg
Number of subjects: 78
Study 11889776 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 5.0 mg
Number of subjects: 78
Study 11889776 — intervention group
Group type: COMPARATOR
Intervention: Epidural administration of 0.25% bupivacaine 40 ml and buprenorphine 0.4 mg
Number of subjects: 78
Study 10391959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 14
Study 10391959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 14
Study 10391959 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol + Salbutamol
Number of subjects: 14
Study 7616870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined norethisterone acetate (NETA)/oestradiol (E2)‐TTS, delivering 0.25 mg NETA and 50 micrograms E2 per day, continuously for 12 calendar months
Number of subjects: 50
Study 1967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble prednisolone (20 mg twice daily on days 1-10 of the female partner's menstrual cycle, followed by 5 mg on days 11 and 12)
Number of subjects: 43
Study 1967425 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 43
Study 1967425 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble prednisolone
Number of subjects: 43
Study 326101 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide aerosol administered every 12 hours for eight weeks
Number of subjects: 36
Study 326101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31323067 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 51
Study 31323067 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (ML)
Number of subjects: 51
Study 28363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg
Number of subjects: 69
Study 28363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 0.5 mg
Number of subjects: 69
Study 28363933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 28363933 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg and 0.5 mg)
Number of subjects: 69
Study 25480607 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed mesenteric defect
Number of subjects: 105
Study 25480607 — intervention group
Group type: COMPARATOR
Intervention: Open mesenteric defect
Number of subjects: 105
Study 22835606 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) with powdered pasteurised egg, starting with 1mg and increasing weekly to 10g over an average duration of 10 weeks.
Number of subjects: 72
Study 22835606 — intervention group
Group type: COMPARATOR
Intervention: Elimination diet (control group).
Number of subjects: 72
Study 22835606 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests with powdered egg at various dilutions after SOTI.
Number of subjects: 72
Study 22835606 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG levels with egg white after SOTI.
Number of subjects: 72
Study 22835606 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE concentration after SOTI.
Number of subjects: 72
Study 21486886 — intervention group
Group type: EXPERIMENTAL
Intervention: User Centred Design format
Number of subjects: 27
Study 21486886 — intervention group
Group type: COMPARATOR
Intervention: Paper format
Number of subjects: 27
Study 21486886 — intervention group
Group type: COMPARATOR
Intervention: CPOE Test format
Number of subjects: 27
Study 21486886 — intervention group
Group type: EXPERIMENTAL
Intervention: All formats
Number of subjects: 27
Study 19925284 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg for six months (Group 1)
Number of subjects: 30
Study 19925284 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 30
Study 16797162 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 382
Study 16797162 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 382
Study 16797162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 12826964 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil/propofol
Number of subjects: 60
Study 12826964 — intervention group
Group type: COMPARATOR
Intervention: isoflurane/fentanyl
Number of subjects: 60
Study 10474065 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 4428 (25 mg)
Number of subjects: 12
Study 10474065 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 4428 (100 mg)
Number of subjects: 12
Study 10474065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8683634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined adjuvant chemotherapy and radiation therapy
Number of subjects: 204
Study 8683634 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiation therapy alone
Number of subjects: 204
Study 1718154 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepartricin
Number of subjects: 71
Study 1718154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 6822108 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 to 30 mg
Number of subjects: 10
Study 6822108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29669001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine 10
Number of subjects: 0
Study 29669001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine 13
Number of subjects: 0
Study 28229515 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy sessions
Number of subjects: 13
Study 28229515 — intervention group
Group type: COMPARATOR
Intervention: Group therapy sessions
Number of subjects: 13
Study 27033905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen 1 mg/kg IV (group DK)
Number of subjects: 32
Study 27033905 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone 0.2 mg/kg IV (group M)
Number of subjects: 32
Study 25026506 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum osteoprotegerin (OPG) levels measured at randomization.
Number of subjects: 4063
Study 21708439 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mgI/kg
Number of subjects: 103
Study 21708439 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mgI/kg
Number of subjects: 103
Study 21708439 — intervention group
Group type: EXPERIMENTAL
Intervention: 630 mgI/kg or more
Number of subjects: 103
Study 21708439 — intervention group
Group type: COMPARATOR
Intervention: 700 mgI/kg
Number of subjects: 103
Study 19720956 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 142
Study 19720956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 17907488 — intervention group
Group type: EXPERIMENTAL
Intervention: External bleaching with 10% carbamide peroxide
Number of subjects: 30
Study 17907488 — intervention group
Group type: EXPERIMENTAL
Intervention: External bleaching with 35% hydrogen peroxide
Number of subjects: 30
Study 17907488 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal/external bleaching with 35% hydrogen peroxide
Number of subjects: 30
Study 17907488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronal bleaching with a paste of sodium perborate mixed with 9% hydrogen peroxide
Number of subjects: 30
Study 17907488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 30
Study 14720266 — intervention group
Group type: EXPERIMENTAL
Intervention: TBC1269 (30 mg/kg)
Number of subjects: 21
Study 14720266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11223496 — intervention group
Group type: EXPERIMENTAL
Intervention: ProBAN sublingual tablets and nicotine gum
Number of subjects: 80
Study 11223496 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets and nicotine gum
Number of subjects: 80
Study 10208287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (CMI)
Number of subjects: 17
Study 10208287 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride (DMI)
Number of subjects: 17
Study 7887003 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral ligaments
Number of subjects: 8
Study 2789749 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutor-guided training
Number of subjects: 72
Study 2789749 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided training
Number of subjects: 72
Study 2789749 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study 1088099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline on admission and 100 mg on the second day
Number of subjects: 4
Study 1088099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of doxycycline on admission only
Number of subjects: 4
Study 1088099 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of doxycycline on admission only
Number of subjects: 4
Study 1088099 — intervention group
Group type: COMPARATOR
Intervention: 500 mg of tetracycline every 6 h for 48 h
Number of subjects: 4
Study 31925529 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy after 1-month ticagrelor and aspirin dual anti-platelet therapy (DAPT)
Number of subjects: 2171
Study 31925529 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin
Number of subjects: 2171
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (targeted screening)
Number of subjects: 58
Study 30477810 — intervention group
Group type: COMPARATOR
Intervention: Control group (opportunistic screening)
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard invitation letter
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced invitation letter
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based care
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of intervention
Number of subjects: 58
Study 30477810 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 58
Study 28685712 — intervention group
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin capsules (SSYX)
Number of subjects: 465
Study 28685712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 26076182 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Internet follow-up for 6 months after discharge
Number of subjects: 128
Study 26076182 — intervention group
Group type: COMPARATOR
Intervention: Routine outpatient follow-up
Number of subjects: 128
Study 23307069 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg of CBD administered post-extinction
Number of subjects: 48
Study 23307069 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg of CBD administered before extinction
Number of subjects: 48
Study 23307069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 48
Study 21708803 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening media use
Number of subjects: 0
Study 21708803 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime media use with violent content
Number of subjects: 0
Study 21708803 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedroom television presence
Number of subjects: 0
Study 21708803 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent daytime media use
Number of subjects: 0
Study 19165663 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 IU of hCG every three days during endometrial preparation with estradiol
Number of subjects: 22
Study 19165663 — intervention group
Group type: COMPARATOR
Intervention: No hCG during endometrial priming with estradiol
Number of subjects: 22
Study 16500921 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol infusion with mixed liquid meal (700 kcal)
Number of subjects: 12
Study 16500921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propranolol) with mixed liquid meal (700 kcal)
Number of subjects: 12
Study 14985214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine (0.6 g.kg(‐1).d(‐1))
Number of subjects: 26
Study 14985214 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glycine (isonitrogenous amounts)
Number of subjects: 26
Study 14985214 — intervention group
Group type: COMPARATOR
Intervention: Control (unsupplemented formula)
Number of subjects: 26
Study 11396393 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics (after one week of forced abstinence)
Number of subjects: 37
Study 11396393 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics (on admission)
Number of subjects: 37
Study 11396393 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 37
Study 11396393 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholics
Number of subjects: 37
Study 11396393 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 37
Study 9420391 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg plain water orally 3 hours before surgery
Number of subjects: 75
Study 9420391 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml/kg plain water and 2 mg/kg of ranitidine orally 3 hours before surgery
Number of subjects: 75
Study 9420391 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasted from midnight)
Number of subjects: 75
Study 9420391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid treated patients (groups II and III)
Number of subjects: 75
Study 8127947 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TRP depletion
Number of subjects: 11
Study 8127947 — intervention group
Group type: COMPARATOR
Intervention: Sham TRP depletion
Number of subjects: 11
Study 3290713 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 48
Study 3290713 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) with lymphocyte counts < 900/mm3
Number of subjects: 48
Study 3290713 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI) with lymphocyte counts > 900/mm3
Number of subjects: 48
Study 3290713 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 48
Study 30911906 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (50 mg) with high-fat meal consumption 30 min before administration
Number of subjects: 16
Study 30911906 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (50 mg) sprinkled on applesauce
Number of subjects: 16
Study 30911906 — intervention group
Group type: COMPARATOR
Intervention: SHP465 mixed amphetamine salts (50 mg) fasting (reference treatment)
Number of subjects: 16
Study 28755607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 70
Study 26925901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 40
Study 26925901 — intervention group
Group type: COMPARATOR
Intervention: Blind corticosteroid injection
Number of subjects: 40
Study 22646219 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 458
Study 22646219 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 150 mg/day
Number of subjects: 458
Study 22646219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 21529923 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 35
Study 21529923 — intervention group
Group type: COMPARATOR
Intervention: Z100
Number of subjects: 35
Study 19909462 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 315
Study 19909462 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 315
Study 20827547 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months
Number of subjects: 250
Study 20827547 — intervention group
Group type: COMPARATOR
Intervention: Alendronate 70 mg orally once weekly
Number of subjects: 250
Study 20827547 — intervention group
Group type: COMPARATOR
Intervention: Denosumab compared to Alendronate
Number of subjects: 250
Study 20827547 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 250
Study 20827547 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 250
Study 15769239 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaders in a positive mood
Number of subjects: 0
Study 15769239 — intervention group
Group type: COMPARATOR
Intervention: Leaders in a negative mood
Number of subjects: 0
Study 12358334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid extract of New Zealand green-lipped mussel (Lyprinol)
Number of subjects: 46
Study 12358334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9655733 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose prednisone (60 mg/d for 1 month, tapered to 40 mg/d for the second month, then 40 mg every other day during the third month)
Number of subjects: 26
Study 9655733 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.6-1.2 mg/d, as tolerated)
Number of subjects: 26
Study 9655733 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 26
Study 7649652 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous back injury
Number of subjects: 175
Study 7649652 — intervention group
Group type: COMPARATOR
Intervention: No previous back injury
Number of subjects: 175
Study 7649652 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic cases attributing symptoms to injury
Number of subjects: 175
Study 7649652 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups attributing symptoms to injury vs. no injury
Number of subjects: 175
Study 2665493 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU oxytocin administered into the umbilical veins
Number of subjects: 40
Study 2665493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 870096 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana cigarette (18 mg of delta‐9‐THC)
Number of subjects: 10
Study 870096 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana cigarette (0.05 mg of delta‐9‐THC)
Number of subjects: 10
Study 870096 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana smoking
Number of subjects: 10
Study 870096 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 10
Study 11375826 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of propofol and small-dose ketamine (propofol 33 +/- 13 microg x kg(‐1) x min(‐1) and ketamine 3.7 +/- 1.5 microg x kg(‐1) x min(‐1))
Number of subjects: 39
Study 11375826 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of propofol and small-dose ketamine
Number of subjects: 39
Study 31500605 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 160
Study 31500605 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) + Androgen deprivation therapy (ADT)
Number of subjects: 160
Study 31500605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study 29490289 — intervention group
Group type: COMPARATOR
Intervention: OC + placebo
Number of subjects: 81
Study 29490289 — intervention group
Group type: COMPARATOR
Intervention: LNG OC + placebo
Number of subjects: 81